Key Takeaways Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly.The Swiss ...

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Taking a page from Eli Lilly and their LillyDirect online pharmacy ... weight loss than Wegovy since it targets two hormones, GLP-1 and GIP. Total Zepbound sales were $4.93 billion in 2024 ...